Johnson & Johnson (JNJ) Total Non-Current Liabilities (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Total Non-Current Liabilities came in at $106.0 billion in Q2 2026, down 6.83% year-over-year from $113.8 billion in Q2 2025, and down 3.21% quarter-over-quarter from $109.5 billion in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Total Non-Current Liabilities across 18 years of filings, most recently posting $106.0 billion for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities fell 6.83% year-over-year to $106.0 billion; the TTM figure through Jun 2026 stood at $106.0 billion (down 6.83% YoY), while the FY2025 annual figure was $107.8 billion, changed 0.37% from the prior year.
- Total Non-Current Liabilities came in at $106.0 billion for Q2 2026 at Johnson & Johnson, down from $109.5 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $124.0 billion in Q2 2023 to a low of $93.7 billion in Q4 2023.
- Average Total Non-Current Liabilities over 5 years is $106.8 billion, with a median of $107.4 billion recorded in 2024.
- Year-over-year, Total Non-Current Liabilities rose 20.16% in 2023 and slipped 18.66% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $100.0 billion in 2022, then retreated by 2.31% to $97.7 billion in 2023, then grew by 9.93% to $107.4 billion in 2024, then rose by 0.37% to $107.8 billion in 2025, then dropped by 1.68% to $106.0 billion in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $106.0 billion in Q2 2026, $109.5 billion in Q1 2026, and $107.8 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 106.45 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 16.16 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 100.86 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 32.04 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | 1.53 Bn |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 1.40 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 607.80 Mn |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | 1.37 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 105.99 Bn |
| Mar 29, 2026 | 109.50 Bn |
| Dec 28, 2025 | 107.80 Bn |
| Sep 28, 2025 | 103.61 Bn |
| Jun 29, 2025 | 113.76 Bn |
| Mar 30, 2025 | 114.33 Bn |
| Dec 29, 2024 | 107.40 Bn |
| Sep 29, 2024 | 106.91 Bn |
| Jun 30, 2024 | 108.30 Bn |
| Mar 31, 2024 | 100.83 Bn |
| Dec 31, 2023 | 97.69 Bn |
| Oct 1, 2023 | 93.66 Bn |
| Jul 2, 2023 | 114.14 Bn |
| Apr 2, 2023 | 123.96 Bn |
| Jan 1, 2023 | 109.45 Bn |
| Oct 2, 2022 | 100.00 Bn |
| Jul 3, 2022 | 100.83 Bn |
| Apr 3, 2022 | 103.16 Bn |
| Jan 2, 2022 | 107.46 Bn |
| Oct 3, 2021 | 108.34 Bn |